November 12, 2010 7:26 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Accretive Health, Inc. (NYSE: AH) reported 3Q 2010 results, Goldman Sachs reports, noting that the EPS of $0.06 and adjusted EBITDA of $32.2 were both in-line with GS/Street estimates.“However, revenues of $158.4 were significantly below our estimate of $174.6mn and Street consensus of $172.4mn,” Goldman Sachs writes. “Management's revenue guidance now stands at $595mn-$607mn (vs prior GS/Street estimates of $645mn/$639mn), while 2010 EBITDA guidance was maintained at $43mn- $46mn.”As a result, Goldman Sachs is reducing its 12 month price target to $13 from $15, which is based on a blend of EV/EBITDA (50%), PEG (20%), and DCF (30%) valuation analyses.Accretive Health currently trades at $9.00.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.